The increase of ldc-c level in human body may block blood vessels and cause vascular sclerosis, which is the precursor of cardiovascular diseases such as atherosclerosis, coronary heart disease and stroke. However, for every 1 mmol / L decrease in LDL-C level, coronary events and cardiac events decreased by 23%, 21% and 19% respectively. According to the updated global guidelines, the target value of LDL-C has been reduced from 80mg / dL to 50mg / dl after several times of reduction. < / P > < p > for example, the jupter study found that when LDL-C levels dropped to 30 mg / dl, some patients benefited more significantly. < / P > < p > in the first clinical end-point trial Fourier study using PCSK9 inhibitors, no serious adverse reactions were observed after the LDL-C level was reduced to 30 mg / dl with elouximab; a further decrease in the risk of cardiovascular events was also observed in individuals who dropped to 10-20 mg / dl, that is, lower than the LDL-C level of newborns.